Oncology Drug Advisory Committee

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023

Retrieved on: 
Wednesday, February 1, 2023
Class Action Lawsuit, Professional Services, Legal, District court, News, Database, Food, Therapy, Oncology Drug Advisory Committee, FDA, Court, Douglas v. U.S. District Court ex rel Talk America, Food and Drug Administration Amendments Act of 2007, BLA, Kirby, Pharmaceutical industry

Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On March 31, 2022, Y-mAbs announced it completed the resubmission of its Biologics License Application (“BLA”) for omburtamab to the Food and Drug Administration (“FDA”).
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Retrieved on: 
Sunday, February 5, 2023
Food, CNS, Bias, Biologics license application, Survival, Oncology Drug Advisory Committee, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Adverse Events, Therapy, News, Pharmaceutical industry, Renewable energy

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB).

Key Points: 
  • NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Y-mAbs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Retrieved on: 
Sunday, January 29, 2023
Food, CNS, Bias, Biologics license application, Survival, Oncology Drug Advisory Committee, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Adverse Events, Therapy, News, Pharmaceutical industry, Renewable energy

NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB).

Key Points: 
  • NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Y-mAbs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023

Retrieved on: 
Tuesday, January 24, 2023
Food, Kirby, Database, Court, News, BLA, Oncology Drug Advisory Committee, Food and Drug Administration Amendments Act of 2007, FDA, District court, Douglas v. U.S. District Court ex rel Talk America, Therapy, Pharmaceutical industry, Private investigator

Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On March 31, 2022, Y-mAbs announced it completed the resubmission of its Biologics License Application (“BLA”) for omburtamab to the Food and Drug Administration (“FDA”).
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SHAREHOLDER ALERT:  Barrack, Rodos & Bacine Encourages Y-mAbs Therapeutics Inc. (YMAB) Shareholders to Contact the Firm About a Recently Filed Securities Class Action Lawsuit

Retrieved on: 
Monday, January 23, 2023
Linda, Complaint, Food, McKesson Corporation, AIG, History, Survival, MCI Inc., Cendant, Oncology Drug Advisory Committee, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Brain, Fraud, News, Pharmaceutical industry

The lawsuit alleges violations of the Securities Exchange Act and names the company and certain of its executives as defendants.

Key Points: 
  • The lawsuit alleges violations of the Securities Exchange Act and names the company and certain of its executives as defendants.
  • According to the Complaint, defendants misrepresented to investors the progress being made toward meeting the FDA’s requirements for demonstrating the drug’s effectiveness.
  • On October 26th, 2022, the FDA released briefing documents in advance of a meeting of the FDA’s Oncologic Drugs Advisory Committee.
  • To read about this lawsuit and to find out additional information about the firm, please see the Barrack, Rodos & Bacine newsroom .

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Retrieved on: 
Thursday, January 19, 2023
Class Action Lawsuit, Professional Services, Legal, Database, News, Oncology Drug Advisory Committee, Therapy, Aerospace, Kirby, District court, FDA, ODAC, Food, BLA, Douglas v. U.S. District Court ex rel Talk America, Court, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Private investigator

Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On March 31, 2022, Y-mAbs announced it completed the resubmission of its Biologics License Application (BLA) for omburtamab to the Food and Drug Administration (FDA).
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

Class Action Involving Spectrum Pharmaceuticals, Inc. (SPPI): Contact Robbins LLP if You Incurred Significant Financial Harm from Your Investment in Spectrum Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, December 28, 2022
Accelerated approval (FDA), Food, Cohort, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Complaint, News, NDA, SPPI, Viability, Patient, CRL, Spectrum Pharmaceuticals, Safety, Oncology Drug Advisory Committee, ODAC, FDA, HER2, Efficacy, Reuters, NSCLC, New Drug Application, Security (finance), Pharmaceutical industry, Drug discovery, Spectrum

Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Key Points: 
  • Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Spectrum Pharmaceuticals.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by February 2, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Spectrum Pharmaceuticals, Inc. (SPPI) Equity Alert: Contact Robbins LLP for Information About the Class Action Against Spectrum Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, December 14, 2022
Spectrum Pharmaceuticals, Oncology Drug Advisory Committee, Accelerated approval (FDA), Viability, NSCLC, Food, FDA, HER2, Safety, News, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRL, Reuters, Efficacy, NDA, ODAC, Complaint, Cohort, SPPI, Patient, Security (finance), Pharmaceutical industry, Spectrum, Drug discovery

Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Key Points: 
  • Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Spectrum Pharmaceuticals.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by February 2, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Spectrum Pharmaceuticals, Inc.

Retrieved on: 
Thursday, December 8, 2022
Spectrum Pharmaceuticals, Oncology Drug Advisory Committee, Accelerated approval (FDA), Viability, NSCLC, Food, FDA, HER2, Safety, News, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRL, Reuters, Efficacy, NDA, ODAC, Complaint, Cohort, SPPI, Patient, Security (finance), Pharmaceutical industry, Spectrum, Drug discovery

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the Securities Exchange Act of 1934.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Spectrum Pharmaceuticals.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by February 2, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.

Retrieved on: 
Monday, December 12, 2022
Class Action Lawsuit, Professional Services, Legal, SPPI, Oncology Drug Advisory Committee, Cohort, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Spectrum Pharmaceuticals, HER2, Patient, NSCLC, New Drug Application, Complaint, FDA, Viability, CRL, ODAC, Efficacy, News, Reuters, Safety, Accelerated approval (FDA), Security (finance), Pharmaceutical industry, Drug discovery, Spectrum

Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Key Points: 
  • Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Spectrum Pharmaceuticals.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by February 2, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.